Early-generation kinase medicines are limited by poor selectivity, off-target effects and the emergence of resistance.

Our founding scientists envisioned a new generation of highly selective kinase medicines that could prolong lives, improve quality of life and prevent disease recurrences, with more potent target inhibition, fewer off-target effects and opportunities for therapeutic combinations.

They worked to build a scalable platform that could yield multiple selective kinase medicines for a wide range of diseases, bringing this innovation to as many patients as possible.

A look inside our labs

Our scientists merge expertise in bioinformatics and structural and cell biology, world-class drug design capabilities and a proprietary library of novel compounds to create a new discovery paradigm. This unique approach enables us to rapidly identify compelling disease targets and design highly selective kinase medicines.

The result is a robust and diverse portfolio of clinical- and research-stage programs targeting genomically defined cancers, rare diseases and cancer immunotherapy. With a steadfast commitment to scientific excellence and to patients, we aim to rapidly and unequivocally change the face of medicine.

Meet our Scientists


Vivek Kadambi: Senior Vice President, Quantitative Pharmacology & Drug Safety Evaluation

My path

I earned a B.Sc. and M.Sc. in Microbiology at the University of Mumbai, and a Ph.D. in Cardiovascular Pharmacology at the University of Cincinnati.

My experience

Working toward my Ph.D. at the University of Cincinnati, I studied in Dr. Litsa Kranias’ laboratory, and completed postdoctoral research in Cardiology/Cardiovascular Pharmacology working with Dr. Kranias and Dr. Brian Hoit. I began my career at Hoechst AG, and came to Cambridge in 1999 to join Millennium Pharmaceuticals (now Takeda), where I worked on first-in-class medicines including Velcade®, Adcetris®, Entyvio® and Integrilin® before joining Blueprint Medicines in 2014.

My biggest achievement

My work at Millennium Pharmaceuticals (now Takeda) aided in the approval of Entyvio®, a first-in-class drug for the treatment of ulcerative colitis and Crohn’s disease.

My recent scientific publications

“Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database,” published in Toxicology and Applied Pharmacology in 2017.

See Vivek's other publications

My Blueprint Medicines

Our team-oriented environment makes it possible for members of the Quantitative Pharmacology and Drug Safety department that I lead, to partner seamlessly to identify and characterize first-in-class compounds.

Grace Silva: Scientist II, Computational Biology

My path

I earned a B.S. from the University of Maryland Baltimore County in Bioinformatics and Computational Biology, and a Ph.D. in Bioinformatics and Computational Biology from the University of North Carolina-Chapel Hill.

My experience

I joined Blueprint Medicines immediately after completing my graduate training at UNC Lineberger Comprehensive Cancer Center, in the laboratory of Charles M. Perou, where our main experimental focus was breast cancer.

My biggest achievement

My work on quantum cascade lasers optimized for sensory systems, which I completed early in my career, has borne out applications in the areas of the environment, healthcare and defense.

My recent scientific publications

“A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer,” published in Breast Cancer Research and Treatment in 2019.

“SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling,” published in Genome Biology in 2017.

“An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer,” published in Nature Genetics in 2014.

See Grace's other publications

My Blueprint Medicines

In joining Blueprint Medicines, I saw both a career path and an opportunity to influence the selection of new drug targets and the development of precision medicine.

Marion Dorsch: Chief Scientific Officer

My path

I earned an M.S. and a Ph.D. in Biology from the Free University of Berlin, Germany.

My Ph.D. thesis was focused on stimulating the anti-tumor immune response  through intratumoral cytokine expression.

My experience

After completing my postdoctoral research at Columbia University, I came to Cambridge, MA and joined Millennium Pharmaceuticals. I then went on to Novartis Institutes of Biomedical Research, Sanofi, and Agios Pharmaceuticals—all in Cambridge—before joining Blueprint in 2016.

My biggest achievement

During my time at Novartis, I led efforts to target the Hedgehog pathway, a developmental  pathway mutated in medulloblastoma and basal carcinoma. My team discovered and developed a small-molecule antagonist of Hedgehog signaling that ultimately became a treatment of metastatic basal cell carcinoma under the trade name ODOMZO®. In parallel we also elucidated novel resistance mechanisms to Hedgehog pathway inhibition and identified additional indications for hedgehog pathway antagonists. Our work was published in high-impact journals.

My recent scientific publications

Co-author, “AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations”, published in Cancer Discovery in 2017

Co-author, “Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation”, published in Science in 2013

Senior author, “Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway”, published in Nature Medicine in 2010

Senior author, “Targeting resistance to Smoothened antagonists by inhibiting the PI3K pathway”, published in Science Translational Medicine in 2010

Senior author, “Discovery of NVP-LDE225, a potent and selective biphenyl-3-carboxamide Smoothened antagonist”, published in ACS Medicinal Chemistry Letters in 2010

See Marion's other publications

My Blueprint Medicines

Our discovery platform –and our immensely talented cross-functional team –empowers us to pursue targets of interest quickly and nimbly. As a result, we’ve been able to deliver multiple clinical programs with proof-of-concept in defined patient populations and a strong portfolio of discovery programs. As a scientist, I find that incredibly motivating.

Chaoyang Ye: Head of Computational Biology & Bioinformatics

My path

I earned a B.S. in Biochemistry from Nanjing University, and a Ph.D. in Microbiology from the University of Missouri-Columbia.

My experience

As a graduate student at the University of Missouri, I studied viral molecular genetics (working in the laboratory of Dr. David Pintel), and completed postgraduate work in genomics at the University of Pennsylvania. At the Allen Institute for Brain Science in Seattle, my team developed novel single cell technologies to study neural differentiation. In 2013, I came to Cambridge to join Novartis, where as a laboratory head I utilized cutting-edge screening and genomics technologies to model neurological diseases before joining Blueprint Medicines in 2018.

My biggest achievement

I was part of an international collaboration to sequence the first two ant genomes and use them as model organisms to study aging. This led to co-first authored papers in Science and Genome Research in 2010 and 2013, respectively.

My recent scientific publications

“Genome-Scale CRISPR Screens Identify Human Pluripotency-Specific Genes,” published in Cell Reports in 2019.

“p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells,” published in Nature Medicine in 2018.

“DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery,” published in Nature Communication in 2018.

See Chaoyang's other publications

My Blueprint Medicines

I joined Blueprint when I realized that my knowledge of genomics and data analytics might have a profound impact on patients’ lives. Each day I work with diverse teams, all dedicated to an expansive project portfolio, and a vast store of data that we can analyze to potentially discover new treatment advances.


“We’re entering a new era of precision medicine… we can now rapidly and reproducibly design potent and selective kinase medicines for previously undruggable as well as newly discovered drivers of disease. Combined with recent advances in molecular profiling, we believe these next-generation kinase medicines can quickly achieve clinical proof-of-concept and, ultimately, transform patient care.”

Marion Dorsch, Ph.D., Chief Scientific Officer

Scientific Advisory Board

Giulio Draetta, M.D., Ph.D.

Director, Institute for Applied Cancer Science at MD Anderson Cancer Center, and Professor of Molecular and Cellular Oncology

Brian Druker, M.D.*

Director, Oregon Health & Science University Knight Cancer Institute, and JELD-WEN Chair of Leukemia Research

Carlos Garcia-Echeverria, Ph.D.

Global Head of Research Platforms, Sanofi

Scott Lowe, Ph.D.*

Member, Cancer Biology and Genetics Program at Memorial Sloan Kettering Institute Cancer Center, and Chair, Geoffrey Beene Cancer Research Center

Nick Lydon, Ph.D.*

Founder, Granite Biopharma LLC

Charles L. Sawyers, M.D.*

Director, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center